Posts by Sonia Cohen, MD, PhD
-
Recent Advances in the Use of Neoadjuvant Immunotherapy in Melanoma
Multiple trials have shown the advantages of adjuvant immunotherapy in patients with high-risk, resectable melanoma. Sonia Cohen, MD, PhD, a surgical oncologist at the Mass General Brigham Cancer Institute, explains why she is now employing neoadjuvant immunotherapy to manage this patient population.
Biography
Sonia Cohen, MD, PhD, is a surgical oncologist caring for patients with sarcoma and melanoma at Massachusetts General Hospital. She received her undergraduate degree from The Johns Hopkins University, her PhD in Genetics from Harvard University, and her medical degree from the Health Science and Technology Program at Harvard Medical School and the Massachusetts Institute of Technology. Dr. Cohen then completed her surgical training at the Massachusetts General Hospital and clinical fellowship in Complex General Surgical Oncology at Memorial Sloan Kettering Cancer Center. Dr. Cohen’s research is focused on understanding how changes in the structure and regulation of the genome give rise to cancer, with a particular focus on developing prognostic tools and novel therapeutics for soft tissue sarcomas and melanomas.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.